The lawsuit alleges that Erasca, along with its top executives, misled shareholders regarding the company's lead drug candidate, ERAS-0015. According to the complaint, the firm marketed the therapy as a "best-in-class" treatment, citing preclinical results that supposedly outperformed Revolution Medicines’ rival drug, RMC-6236. Plaintiffs claim these comparisons were fundamentally flawed, lacked a reasonable basis, and ignored significant patent and trade secret liabilities.
In section Releases
Investors Face August Deadline in Erasca Securities Fraud Lawsuit
Investors who lost more than $100,000 in Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, have until August 10 to petition the court to serve as lead plaintiff in a pending securities class action filed against the oncology-focused biopharmaceutical company.
Rosen Law Firm, representing the investors, stated that these omissions harmed shareholders when the actual details of the drug's development and legal standing surfaced. While the court has not yet certified a class, affected investors may participate in the litigation or choose their own counsel. Those wishing to act as a lead plaintiff must file their motion by the August 10 deadline. Participation does not require out-of-pocket costs, as the case proceeds under a contingency fee arrangement.
Comments (0)
No comments yet. Be the first!